Abstract
Purpose: The chance to get healing in stomach cancer is possible with curative surgical resection. In this study we aimed to analyze the mortality and morbidity rates between D1 dissection and D2 dissection retrospectively.
Materials and Methods: Between 2000 and 2009, 112 patients with gastric cancer who underwent D1 or D2 dissection were evaluated retrospectively. Surgery procedure and pathological classification were performed in accordance with the Japanese Classification of Gastric Carcinoma. The postoperative mortality and morbidity were analysed retrospectively.
Results: In our clinic, the data of 131 patients, who had the diagnosis of gastric carcinoma, were reviewed retrospectively. 112 patients who fitted to the criteria of this study were included. Of the 112 patients, 47 went under D1 dissection, while 67 patients went under D2 resection. The overall operative mortality rates for D1 and D2 dissections were 2,1 and 0 %, respectively (p>0.05). Patients who underwent D2 dissection had significantly longer median operation time, more blood loss and more transfusion required in comparison to patients who underwent D1 dissection. The overall morbidity associated with surgery is found to be at a rate of 15,1 %. There was no significant difference between the two groups with regard to the major complications. However, when minor complications were assesed, a significant increase in the D2 group was observed. The overall mortality rate was calculated as 0.89 %.
Conclusion: In our study, although extensive dissection had an increased morbidity, there was no significant statistical difference between the two procedures. As a conclusion, we think that D2 dissection can be carried out with safety in centers with experience.
Keywords:
Gastric cancer, lymph node dissection, gastric resection, gastrectomy
References
1Coleman MP, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mortality. In: IARC Scientific Publications: 1993.
2Allum WH, Griffin SM, Watson A, et al. Guidelines for the management of oesophageal and gastric cancer. Gut 2002; 50: 1–23.
3Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric Cancer Surgery: Morbidity and Mortality Results from a Prospective Randomized Controlled Trial Comparing D2 and Extended Para- Aortic Lymphadenectomy-Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004; 22, 14, 2767-2773.
4NHS Executive: Guidance on Commissioning Cancer Services: Improving outcomes in uppergastro-intestinal cancers, 2001.http://www.dh.gov.uk/asset- Root/04/08/02/78/04080278.pdf
5Çetiner S, Tan A, Sarıçam T, Yakut M, Kaymakçıoğlu N, Akdeniz A. Mide kanserinde genişletilmiş lenf nodu diseksiyonunun yeri. Ulusal Cerrahi Dergisi 1999;3:149-156
6Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995; 82:346-351
7Parikh D, Johnson M, Chagla L, Lowe D, McCulloch P. : D2 gastrectomy: Lessons from a prospective audit of the learning curve. Br J Surg 1996, 83:1595-1599.
8International Union against Cancer: TNM Classification of Malignant Tumors (Ed 6). New York, NY, Wiley-Liss, 2002.
9Kajitani T: Japanese Research Society for the Study of Gastric Cancer. The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981;11:127-
10Japanese Research Society for Gastric Cancer: Japanese Classification of Gastric Carcinoma (1st English Ed). Tokyo, Japan, Kanehara, 1995.
11Sano T, Katai H, Sasako M, Maruyama K. One thousand consecutive gastrectomies without operative mortality. Br J Surg 2002;89:123.
12Buğra D. Mide Kanserinde Genişletilmiş Lenf Bezi Disseksiyonu Sağ Kalım, Morbidite ve Mortalite Üzerine Etkileri. Ulusal Cerrahi Dergisi 1999; 5:269-281
13Siewer JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: Ten year results of the German gastric cancer study. Ann Surg 1998; 228:449-461.
14Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: Who may Benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;11: 2069-2077 .
15Griffith JP, Sue-Ling HM, Martin I, Dixon MF, McMahon MJ, Axon AT, Johnston D. Preservation of the spleen improves survival after radical surgery for gastric cancer. Gut 1995;36: 684-690.
16Roukos DH, Lorenz M, Encke A: Evidence of survival benefit of extended (D2) lymphadenectomy in Western patients with gastric cancer based on a new concept: A prospective long term follow-up study. Surgery 1998;123:573-578.
17Kodera Y, Yamamura Y, Shimizu Y, Torii A, Hirai T, Yasui K, Morimoto T, Kato T,Kito T. Lack of benefit of combined pancreaticosplenectomy in D2 resection for proximal-third gastric carcinoma. World J Surg 1997; 21: 622–628.
18Kitamura K, Nishida S, Ichikawa D, Taniguchi H, Hagiwara A, Yamaguchi T, Sawai K. No survival benefit from combined pancreaticosplenectomy and total gastrectomy for gastric cancer. Br J Surg 1999;86: 119-122.
19Hermanek P, Altendorf-Hofmann A, Mansmann U, Dworak O, Wittekind C, Hohenberger W. Improvements in staging of gastric carcinoma using the new edition of TNM classification. Eur J Surg Oncol 1998;24:536–541.
20Klein Kranenbarg EK, Hermans J, van Krieken JHJM, van de Velde CJ. Evaluation of the fifth edition of the TNM classification for gastric cancer: Improved prognostic value. Br J Cancer 2001;84:64-71.
21Gunderson LL, Sosin H. Adenocarcinoma of the stomach: Areas failure in reoperation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8: 1-11.
22Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S. Randomised trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cystosine arabinoside followed by oral fluorouracil in seronegative gastric cancer: Japan clinical oncology group 9206-1. J Clin Oncol 2003; 21:2282-2287.
23Maruyama K, Gunven P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. Ann Surg 1989; 210:596-602.
24Davis P, Sano T: The difference in Gastric cancer between Japan, USA and Europe: What are the facts? What are the suggestions? Crit Rev Oncol Hematol 2001; 40: 77-94.
25Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137.
26Msika S, Benhamiche AM, Tazi MA, Rat P, Faivre J. Improvement of operative mortality after curative resection for gastric cancer: Population based study. World J Surg 2000;24:1137-1142.
27McCulloch P. Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980-1985. Br J Surg 1994; 81:417-420.
28Bonenkamp JJ, Sogun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745- 748.
29Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial- The Surgical Cooperative Group. Lancet 1996;347:995- 999.
30Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. D2 lymphadenectomy alone or with paraaortic nodal dissection for gastric cancer. N Engl J Med. 2008;31: 453–462.
